"We are very happy about this price reduction for a needed assay to better and more rapidly detect MDR-TB and XDR-TB. These results are also a direct outcome of a fruitful collaboration with public and private partners such as UNITAID and BD," said Dr. Giorgio Roscigno, FIND Chief Executive Officer. "During a time of severe economic distress, resources are constrained and high-burden countries face intensified healthcare challenges. This agreement means that it will be possible to make this test more accessible and affordable to those who need it most, which is very encouraging and promising."
"With financial support from UNITAID, state-of-the-art technologies to diagnose MDR-TB are being introduced in low-income countries for the first time by FIND, GLI and GDF," said Jorge Bermudez, Executive Secretary of UNITAID. "UNITAID has also approved the expansion of the project with a new grant of US$ 61 million to extend access to these superior tests to an additional 11 high burden countries."
Under the terms of the agreement, the reagents will now be discounted 80%. Slight price variations will occur for end users because of shipping costs, tariffs, fees and other local costs that vary from country to country. The agreement provides for potential added discounts as test tube volume expands.
BD and FIND said they were able to accelerate the program with the help of financial support from a consortium consisting of UNITAID, the Global Laboratory Initiative and Global Drug Facility, along with FIND itself.
Over the next four years it is expected that partners GDF, GLI and FIND will provide equipment, reagents and technical expertise in identified countries for modernizing and expanding TB laboratory diagnostic capacity.
FIND and BD had announced the initial pricing agreement
|SOURCE BD (Becton, Dickinson and Company)|
Copyright©2009 PR Newswire.
All rights reserved